title: Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients.
abstract: The main metabolites of noradrenalin, dopamine, and serotonin-3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), respectively--were estimated in plasma of 21 depressed patients before and after 2 and 4 weeks of treatment with the monoamine oxidase-type A (MAO-A) inhibitor moclobemide (mean final daily dose = 8.9 mg/kg body weight). The treatment caused significant mean reductions in plasma MHPG and HVA (46% and 30%, respectively), while plasma 5-HIAA was unchanged. Multiple regression analysis revealed associations between reductions in MHPG and changes on the anxiety-somatization factor of the Hamilton Rating Scale for Depression (HRSD), and between reductions in HVA and changes in the HRSD factors cognitive disturbance and retardation.
authors.affiliation: Psychiatric Clinic, Athens University Medical School, Eginition Hospital, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Markianos
authors.forename: B
authors.initials: B
authors.lastname: Alevizos
authors.forename: J
authors.initials: J
authors.lastname: Hatzimanolis
authors.forename: C
authors.initials: C
authors.lastname: Stefanis
mesh_terms: D000328:Adult; D001143:Arousal / Q000502:physiology; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001679:Biogenic Amines / Q000097:blood*; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004298:Dopamine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood; D010555:Personality Inventory; D012701:Serotonin / Q000097:blood
chemical_list: D001549:Benzamides; D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D020912:Moclobemide; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid